来那替尼

来那替尼（CAS 698387-09-6）的独立参考数据，整理自公开化学数据库。

各数据库的登记标识

计算分子描述符

在册的记载用途

For use as an extended adjuvant treatment in adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.Neratinib is an orally available tyrosine kinase receptor inhibitor that is used in the extended adjuvant therapy of early stage breast cancer. Neratinib is associated with a low rate of transient elevations in serum aminotransferase levels during therapy, but has not been convincingly linked to cases of clinically apparent liver injury with jaundice.

同义词与商品名

Neratinib; 698387-09-6; HKI-272; HKI 272; JJH94R3PWB; PB-272; CHEBI:61397; CDP-820; PB 272; HKI272; DTXSID70220132; N-(4-(3-Chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide; neratinibum; RefChem:56993; DTXCID70142623; L10XE45

已收录的法规名录

GHS notification summary	20% (1 / 5)

GHS 危害分类

GHS notification summary	20% (1 / 5)
Reported hazard statements	H302 (40%), H312 (40%), H315 (40%), H319 (40%), H332 (40%), H335 (20%), H360 (40%)

This chemical does not meet GHS hazard criteria for 20% (1 of 5) of reports.

H302 (40%): Harmful if swallowed [Warning Acute toxicity, oral]

公开数据库对它的描述

Neratinib · CAS 698387-09-6 · C30H29ClN6O3. UNII JJH94R3PWB.

物理形态与操作说明

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。